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Among diet components, some fatty acids are known to aﬀect several stages of colon carcinogenesis, whereas others are probably
helpful in preventing tumors. In light of this, our aim was to determine the composition of fatty acids and the possible correlation
with apoptosis in human colon carcinoma specimens at diﬀerent Duke’s stages and to evaluate the eﬀect of enriching human
colon cancer cell line with the possible reduced fatty acid(s). Specimens of carcinoma were compared with the corresponding non-
neoplastic mucosa: a signiﬁcant decrease of arachidonic acid, PPARα, Bad, and Bax and a signiﬁcant increase of COX-2, Bcl-2,
and pBad were found. The importance of arachidonic acid in apoptosis was demonstrated by enriching a Caco-2 cell line with this
fatty acid. It induced apoptosis in a dose- and time-dependent manner via induction of PPARα that, in turn, decreased COX-2. In
conclusion, the reduced content of arachidonic acid is likely related to carcinogenic process decreasing the susceptibility of cancer
cells to apoptosis.
Copyright © 2009 Manuela Oraldi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Colon carcinoma is one of the world’s most widespread
tumors and appears to be correlated with diet [1]. Although
the disease may evolve from genetic alterations in pro-
tooncogenes ortumorsuppressorgenes[2],thereisevidence
indicating that some dietary factors, such as fat and ﬁber,
can also aﬀect several stages of colon carcinogenesis [3, 4].
Among diet components, lipids are perceived as dangerous,
although some lipids, such as certain polyunsaturated fatty
acids (PUFAs), are considered to be positive for human
health, preventing tumors and cardiovascular diseases [5–
7]. Thus dietary adjustment aimed at preventing colorectal
carcinoma is increasingly becoming an interesting option
[8].
However, little is known about the composition of fatty
acids in human colon carcinoma tissue versus that of non-
neoplastic mucosa or about any changes in this composition
during tumor development. Some ﬁndings have shown a
decrease in PUFAs, such as linoleic and α-linolenic acids,
together with an increase in free arachidonic acid, in colon
cancer tissue versus those of a normal human large intestine,
whereas other data have indicated an increase in linoleic
acid and a decrease in α-linolenic and arachidonic acids
[9–11].
More is known about the eﬀect of PUFAs on cell
lines and on the development of carcinoma in animals
models. Supplementing cell lines with n-3 or n-6 PUFAs
leads to an increased incorporation of these PUFAs in
membranephospholipids,inﬂuencingnotonlycellstructure
but also cell functions, including immunological response,
proliferation, and survival [12–15]. Feeding animals with n-
3 PUFAs has been found to inhibit tumor growth, probably
because of the altered fatty acid composition [16, 17].
The eﬀects of PUFAs on cell function and viability may
be related to the fact that they and their metabolites are
important mediators of the intracellular signal networks;
that is, they may have an eﬀect on gene expression after
binding with peroxisome proliferator activated receptors
(PPARs).PPARsarepresentincellsinthreeisoforms(α,β,γ)
and play an important regulatory role in lipid metabolism
and cancer development [15, 18, 19].2 Journal of Oncology
Among PUFA metabolites, the prostaglandines (PGs),
which are derived from arachidonic acid, have been studied
in depth. The PGE2 level has been shown to be signiﬁcantly
elevated during inﬂammation and in cancer, and this ﬁnding
has been attributed to the increased expression of the
inducible cyclo-oxygenase 2 (COX-2) [20]. The functions of
COX-2-derived PGE2 in malignant and metastatic disease
have been widely studied, and it appears to play a role
in tumor invasion, in stimulating angiogenesis, and in
modulating apoptosis [21, 22].
There is considerable controversy over the frequency of
apoptotic cell death in the adenoma-carcinoma sequence
in the human colon. Most researchers have found that the
apoptotic index was higher in carcinoma than in normal
colonic mucosa and adenomas, even though Tsujitani et al.
reported a lower apoptotic rate in carcinoma, in a study
comparing carcinomatous with adenomatous components
in the same tumors [23, 24].
In light of the limited knowledge of the apoptotic
events in colon cancer, and since PUFAs can modulate
cancer development by regulating cell proliferation and/or
viability, this study examined specimens of human colon
carcinoma at diﬀerent stages of Duke’s classiﬁcation and
the corresponding non-neoplastic mucosa. The aim was to
evaluate any changes in fatty acid content of phospholipids,
in expression of some proteins regulating apoptosis and in
PPARα, whose fatty acids are ligands. COX-2, the enzyme
responsiblefortheproductionoffattyacidmetabolitesactive
in cancer induction, was also analyzed.
To corroborate the results obtained in vivo, human colon
carcinoma Caco-2 cells were used to evaluate the eﬀect of
arachidonic acid, an ω-6 fatty acid, in modulating apoptosis.
2.MaterialsandMethods
2.1. Colon Tissue Specimens. Colon adenocarcinoma and
adjacent non-neoplastic colonic mucosa specimens were
obtained from 28 surgical patients at the Oncology Center,
Molinette Hospital, Turin, Italy. Adjacent connective tissue
was stripped away in all cases, to ensure that there was no
fatcontamination, andcolonic cancerspecimens werefree of
non-neoplastic colon mucosa. Specimens were immediately
frozen and stored at −80
◦C. Resected cancers were staged,
accordingtoDuke’sclassiﬁcation,asAin3cases,Bin8cases,
C in 11 cases and D in 6 cases.
Human samples were collected and analyzed with the
full understanding and consent of the patient. Responsible
Ethical Committee has approved these experiments.
2.2. Cell Cultures. Human colon cancer cells Caco-2 (ATCC,
USA) were seeded (30000cells/cm2) and maintained for
48 hours in DMEM+GlutaMAX-1 medium containing 1%
antibiotic/antimycotic solution (medium A), supplemented
with 10% fetal bovine serum (FBS), and maintained at 37
◦C
in a humidiﬁed atmosphere of 95% air and 5% CO2.
2.3. Caco-2 Cell Diﬀerentiation. Cells were maintained in
culture for 2 and 20 days. After harvesting the cells were
examined for arachidonic acid percentage content and
for alkaline phosphatase (ALP) activity as diﬀerentiation
marker. ALP activity was determined as in [25].
2.4. Arachidonic Acid Supplementation. As t o c ks o l u t i o n
of free arachidonic acid (100mM in FBS) was prepared
a n ds t o r e da t−20
◦C until use. Twenty four hours after
seeding undiﬀerentiated cells, culture medium was removed
and replaced by medium B (medium A plus 0.4% serum
bovine albumin (fatty acid free), 1% vitamin solution,
1% nonessential amino acids) supplemented or not with
arachidonic acid (time 0). Arachidonic acid stock solution
was diluted to the ﬁnal concentration directly in medium B,
used to replace medium A. FBS alone was added to control
cells.
At the experimental times indicated in the ﬁgures, Caco-
2 cells, treated or not with arachidonic acid, were trypsinized
aftercollectingculturemedium,harvestedandcentrifugedat
600g for 10 minutes, to determine apoptosis parameters.
2.5. Treatment of Cells with PPARα Antagonist MK886 or
with COX-2 Inhibitor NS398. C a c o - 2c e l l sw e r et r e a t e d
with arachidonic acid, as described above, and with the
PPARα antagonist MK886 or COX-2 inhibitor NS398. 2μM
MK886 was administered to the cells when arachidonic acid
was added (time 0), and 50μM NS398 one hour before
arachidonic acid addition.
2.6. Apoptosis Evaluation. Percentages of viable, necrotic,
or apoptotic cells were evaluated by determining the DNA
content after propidium iodide staining in ﬂowcytometry as
described in [18].
The presence of apoptotic cells was also shown by
staining cells with DAPI (4 , 6-diamidino 2-phenylindole)
then observing them using ﬂuorescence microscopy.
2.7. Analysis of Fatty Acid Composition in Phospholipids. The
percentage content of diﬀerent fatty acids was determined
in the polar lipids extracted from non-neoplastic and colon
cancer specimens and from Caco-2 cells as described in [19].
The percentage of single fatty acids was calculated taking the
content of total fatty acids in phospholipids as 100%. Methyl
heptadecanoate was added to each preparation as internal
standard.
2.8. Western Blot Analysis. For each colon specimen, about
50mg of tissue was washed twice in cold PBS and then
homogenized by sonication in 150μLo fT o t e xb u ﬀer (pH
7.9) containing 20mM Hepes, 350mM NaCl, 20% glyc-
erol, 1% NP-40 substitute, 1mM MgCl2,0 . 5 m ME D T A ,
0.1mM EGTA, 1mM Na-orthovanadate, 1mM phenyl
methyl sulfonyl ﬂuoride (PMSF), 5mM DL-Dithiothreitol,
and 15μg/mL leupeptin. The homogenates were kept on
ice for 1 hour and then centrifuged in a microfuge at
13500rpm for 25 minutes. Supernatants containing the
extracted proteins were then collected and used for Western
blot analysis as described in [18].Journal of Oncology 3
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Figure 1: Protein content of COX-2, PPARα, and Bcl-2 in cancer specimens and corresponding non-neoplastic mucosa. The densitometry
value for PPARα and Bcl-2, referred to the corresponding β-actin value, was compared with that of the corresponding non-neoplastic
mucosa, taken as 1. The data are expressed in means ± SD. Since COX-2 was not expressed in all mucosa specimens, the same comparative
data as for PPARα is not available. Signiﬁcant diﬀerences between cancer specimens and relative mucosa specimens were assessed by the
Wilcoxon signed rank test (∗P<. 05). Signiﬁcant diﬀerences among cancer groups at diﬀerent Duke’s stages were assessed by variance
analysis followed by the post hoc Newman-Keuls test. C+: positive control.
The membranes were incubated with polyclonal anti-
PPARα, Bcl-2, pBAD, BAD and Bak, with monoclonal
anti-COX-2 (all purchased from Santa Cruz Biotechnology,
Heidelberg, Germany), or anti- β-actin (purchased from
Sigma, Mo, USA) antibodies. The densitometry value for
each protein was referred to the corresponding β-actin value.
Collected Caco-2 cells were suspended to 50% (w/v) in
lysis buﬀer containing 20mM Tris-HCl (pH 7.4), 150mM
NaCl,5mMEDTA,1%NP-40substitute,1mMPMSF,1mM
Na-orthovanadate, and 15μg/mL leupeptin. Cells were then
incubated for 30 minutes on ice and sonicated 3 times for
3 seconds. After centrifugation, the extracted proteins were
used for Western blot analysis as described above. PPARα,
Bcl-2, Bak, and COX-2 were evaluated.
2.9. Protein Determination. Protein content was determined
with the Protein Assay Kit 2 (BIO-RAD Laboratories, CA,
USA).
2.10. Statistical Analysis. Data for fatty acid percentage
content in cancer and corresponding mucosa specimens are
expressed as means ± SD. Signiﬁcant diﬀerences between
all cancer and their corresponding mucosa specimens, and
those among cancer groups at diﬀerent stages of Duke’s
classiﬁcation, were assessed by variance analysis, followed by
the post hoc Newman-Keuls test.
Protein content data are expressed as means ± SD,
calculated by relating the values in cancer specimens to
those in mucosa ones, taken as 1. Signiﬁcant diﬀerences
between cancer and the corresponding mucosa specimens
were assessed by the Wilcoxon signed rank test; signiﬁcant
diﬀerences among cancer groups at diﬀerent stages of Duke’s
classiﬁcation were assessed by variance analysis, followed by
the post-hoc Newman-Keuls test.
Signiﬁcant diﬀerences between Caco-2 cells treated with
arachidonic acid or untreated were assessed by variance
analysis, followed by post hoc Newman-Keuls test.
3. Results
3.1. Human Colon Cancer Specimens
3.1.1. Colon Cancer Classiﬁcation. Colon non-neoplastic
mucosa and carcinoma specimens were obtained from 28
surgical patients (15 women, 13 men; age range 32 to 87
years; mean 67.50 ± 11.69). Carcinomas ranged from well
to poorly diﬀerentiated and were at the following stages of
Duke’s classiﬁcation: 3 cases of resected cancers were in stage
A, 8 cases in B, 11 cases in C, and 6 cases in D.
3.1.2. Fatty Acid Composition in Phospholipids. Table 1
reports the percentage of the content of various PUFAs in
phospholipids extracted from cancer specimens at diﬀerent
Duke’s stages and from the corresponding non-neoplastic
mucosa. Table 1 also reports the sum (

)o fP U F A sa n do f
monounsaturated fatty acids (MUFAs) plus saturated fatty
acids. The table also shows the signiﬁcance of diﬀerences
between mucosa and tumor specimens; the signiﬁcance
among tumor specimens at diﬀerent Duke’s stages was not
reported, since there were no diﬀerences.4 Journal of Oncology
Table 1:Percentageofthecontentofpolyunsaturatedfattyacidsinphospholipidsextractedfromcoloncancerspecimensandcorresponding
non-neoplastic mucosa.
Fatty acids ABCD
Mucosa Tumour Mucosa Tumour Mucosa Tumour Mucosa Tumour
18 : 2 12.5 9.1 10.1 8.9 12.1 10.7 12.5 7.6∗
18 : 3 0.2 0.7 0.4 0.3 1.0 1.1 0.8 0.6
CLA 0.5 0.5 1.4 0.2∗ 1.2 0.5∗ 0.7 0.2∗
20 : 4 11.0 7.1∗ 11.4 8.1∗ 11.6 7.7∗ 13.4 9.5∗
22 : 6 1.0 1.5 1.8 1.5 1.6 1.8 2.4 1.9

PUFA 25.2 18.9∗ 25.1 19.0∗ 27.6 21.3∗ 29.9 19.8∗

MUFA + saturated 74.8 81.1∗ 74.9 81.1∗ 72.4 78.7∗ 70.1 80.2∗
The SD was not more than 10%. For each fatty acid, the variance analysis followed by post hoc Newman-Keuls test was carried out. The table only shows the
signiﬁcance of diﬀerences between mucosa and tumor specimens (∗ tumour versus mucosa, P<. 05). The diﬀerences among tumour specimens at diﬀerent
D u k e ’ ss t a g e s( A ,B ,C ,D )w e r en o ts i g n i ﬁ c a n t . 
PUFA: sum of all polyunsaturated fatty acids;

MUFA + saturated: sum of all monounsaturated and saturated fatty acids.
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Figure 2: Protein content of Bak, Bad, and p-Bad in cancer specimens and corresponding non-neoplastic mucosa specimens. The
densitometry values, the data, and signiﬁcant diﬀerences are as in Figure 1.
Comparing the percentage of the content of each PUFA
in cancer specimens and in the corresponding mucosa,
a signiﬁcant decrease was seen in arachidonic acid at all
Duke’s stages, for linoleic acid at stage D, and for CLA
at stages B, C, and D. On the contrary, no diﬀerence was
found for linolenic or docosaexaenoic acids. The decreases
in linoleic and arachidonic acids and in CLA accounted for
the decreased

PUFA content observed at all Duke’s stages.
3.1.3. COX-2 Content. In view of the decreased arachidonic
acidpercentage,theproteincontentofCOX-2wasevaluated.
It was found to be increased in cancer specimens versus
mucosa specimens. Figure 1 shows a typical COX-2 Western
blot:theproteinwasnotexpressedinnon-neoplasticmucosa
and was increased in carcinoma at all stages. Since COX-
2 was not expressed in all mucosa specimens, the same
comparative data are not available for this protein.
3.1.4.PPARαContent. Sincefattyacidsandtheirmetabolites
are preferential ligands of PPARα, the protein content of
this nuclear receptor was evaluated (Figure 1), showing a
decreaseincarcinomaversusmucosaatallDuke’sstageswith
no signiﬁcant diﬀerences among Duke’s stages.
3.1.5. Apoptosis Parameters. The antiapoptotic protein Bcl-2
and inactive phosphorylated form of Bad (Figures 1 and 2)Journal of Oncology 5
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Figure 3: Percentage of the content of arachidonic acid and
percentageofcellsinapoptosisinhumanCaco-2cells48hoursafter
enrichment with arachidonic acid. Data are expressed in means ±
SD of 4 experiments. For arachidonic acid and for apoptosis means
with diﬀerent letters are signiﬁcantly diﬀerent from one another
(P<. 05), as determined by variance analysis followed by post hoc
Newman-Keuls test. For percentage of the content of arachidonic
acid; diﬀ:d i ﬀerentiated Caco-2 cells; undiﬀ: undiﬀerentiated Caco-
2 cells; undiﬀ + AA25: undiﬀerentiated Caco-2 cells treated with
25μM arachidonic acid; undiﬀ + AA50: undiﬀerentiated Caco-
2 cells treated with 50μM arachidonic acid; undiﬀ + AA100:
undiﬀerentiated Caco-2 cells treated with 100μM arachidonic acid.
For percentage of cells in apoptosis: C: control cells; AA25: cells
treated with 25μM arachidonic acid; AA50: cells treated with 50μM
arachidonic acid; AA100: cells treated with 100μM arachidonic
acid; MK: cells treated with 2μM MK886.
were increased in all cancer specimens, with no diﬀerences
among Duke’s stages, whereas the proapototic proteins Bad
and Bak were decreased (Figure 2).
3.2. Human Colon Cancer Cells Caco-2
3.2.1. Arachidonic Acid Content. Figure 3 shows the percent-
age content of fatty acids in phospholipids extracted from
diﬀerentiatedandundiﬀerentiatedCaco-2cells,showingthat
arachidonic acid is present in higher percentage content in
diﬀerentiated cells than in undiﬀerentiated cells (3.7 versus
9.4, resp.). Enriching undiﬀerentiated cells with 25, 50, or
100μM arachidonic acid, the percentage content of this
fatty acid increased reaching a value of 15 with 100μM
arachidonic acid.
C
AA25
AA50
AA100
MK886
AA25 + MK
AA50 + MK
AA100 + MK
Figure 4: Apoptosis in human Caco-2 cells 48 hours after enrich-
ment with arachidonic acid. Apoptosis was determined by staining
the cells with DAPI. C: control cells; AA25: cells treated with 25μM
arachidonic acid; AA50: cells treated with 50μM arachidonic acid;
AA100:cellstreatedwith100μMarachidonicacid;MK:cellstreated
with 2μM MK886.
3.2.2. Apoptosis and PPARα Content. The increased arachi-
donic acid content in treated-cells aﬀected cell viability,
inducing apoptosis, as shown in Figure 3.A p o p t o s i sw a s
also shown by DAPI staining (Figure 4): arachidonic acid-
treated cells showed fragmented and condensed nuclei, and
apoptotic bodies; on the contrary, in untreated cells few
apoptotic ﬁgures were observed.
The involvement of arachidonic acid in modulating
apoptosis was conﬁrmed by analyzing the antiapoptotic
protein Bcl-2 and the proapoptotic proteins Bak and caspase
3. Figure 5 shows a decrease of the ﬁrst protein and an
increase of the second ones in arachidonic-treated cells in
comparison with control cells. Caspase 3 induction was
shown by an increased amount of cleaved form.
Figure 6 reports the PPARα content, demonstrating
an increase of this nuclear receptor in treated cells. Its
involvement in arachidonic acid-induced apoptosis was6 Journal of Oncology
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Figure 5: Protein content of Bcl-2, Bak, and caspase 3 in Caco-2 cells 48 hours after enrichment with arachidonic acid. Data are expressed in
means ± SD of 4 experiments. Means with diﬀerent letters are signiﬁcantly diﬀerent from one another (P<. 05), as determined by variance
analysis followed by post hoc Newman-Keuls test. The densitometry values, referred to as the corresponding β-actin value, were compared
with those of control cells, taken as 1. C: control cells; AA25: cells treated with 25μM arachidonic acid; AA50: cells treated with 50μM
arachidonic acid; MK: cells treated with 2μM MK886.
demonstrated by treating the cells with the speciﬁc PPARα
antagonist MK886. Figures 3 and 4 show that MK886
prevented apoptosis induction and growth inhibition due
to arachidonic acid. The reverting eﬀect of MK886 was
also conﬁrmed by DAPI staining. The prevention of
apoptosis induction was further conﬁrmed by evalua-
tion of anti- and proapoptotic proteins (Figure 5). Bcl-
2 level was increased in the cells treated with arachi-
donic acid and MK886 in comparison with the cells
treated with arachidonic acid alone, whereas Bak was
decreased.
3.2.3. COX-2 Content. The evaluation of COX-2 in Caco-2
cells enriched with arachidonic acid showed that the lowest
concentration of fatty acid slowly increased the enzyme
content, whereas the highest concentration decreased it
(Figure 6). PPARα antagonist MK886, which did not
induce apoptosis, increased COX-2 content. To demon-
strate that COX-2 was involved in blocking apoptosis,
speciﬁc COX-2 inhibitor NS398 was used, showing that
it increased apoptotic cell percentage in comparison with
untreated cells. Cells treated with both arachidonic acid
and COX-2 inhibitor showed a further increase in apoptosis
(Figure 6).
4. Discussion
The study is focused on the fatty acid content in phospho-
lipids of human colon cancer samples of diﬀerent degrees of
malignancy and on some factors regulating apoptosis. The
observations suggested by the results obtained with cancer
specimens were conﬁrmed using “in vitro” experiments
using Caco-2 cells.
The most signiﬁcant diﬀerences between colon cancer
specimens and the corresponding non-neoplastic mucosa
were as follows: (1) the percentage of the content of

PUFAs, linoleic acid, CLA, and arachidonic acid decreased;
(2) COX-2 increased in cancer specimens, whereas in
non-neoplastic mucosa it was not expressed; (3) PPARα
decreased; (4) the antiapoptotic proteins Bcl-2 and pBad
increased, whereas the proapototic proteins Bad and Bak
decreased.
The results in cancer specimens were also correlated
with the patients’ clinical stage but showed no evidence
that the clinical stage inﬂuenced the parameters examined.
In view of this, it is possible to hypothesize that changes
in some parameters, such as PUFA and proteins involved
in apoptosis, are important for the entire carcinogenesis
process.Journal of Oncology 7
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Figure 6: Protein content of PPARα and COX-2 and percentage of cells in apoptosis in human Caco-2 cells 48 hours after enrichment with
arachidonic acid and COX-2 inhibitor NS398. Data are expressed in means ± SD of 3 experiments. For COX-2 and for apoptosis means with
diﬀerentlettersaresigniﬁcantlydiﬀerentfromoneanother(P<. 05),asdeterminedbyvarianceanalysisfollowedbyposthoc Newman-Keuls
test. For PPARα and COX-2, the densitometry values, referred to as the corresponding β-actin value, was compared with those of control
cells, taken as 1. C: control cells; AA25: cells treated with 25μM arachidonic acid; AA50: cells treated with 50μM arachidonic acid; MK: cells
treated with 2μM MK886. For percentage of cells in apoptosis, C: control cells; AA50: cells treated with 50μM arachidonic acid; NS: cells
treated with 50μM NS398; AA50 + NS: cells treated with 50μM arachidonic acid plus 50μM NS398.
The low arachidonic acid content present in colon cancer
was also evident in undiﬀerentiated Caco-2 cells. It is
noteworthy that the content of this fatty acid in Caco-2 cells
is in relation to the degree of deviation. In fact, its percentage
waslowerinundiﬀerentiatedcellsthanindiﬀerentiatedcells,
pointing again to the importance of arachidonic acid in the
development of tumours.
The reduced content of arachidonic acid might be also
consideredadefensemechanismwherebycancercellsprotect
themselves from the cytotoxic eﬀect of this compound. In
fact, the low level of arachidonic acid was accompanied
by an increase in antiapoptotic protein Bcl-2 and by the
reduction of proapototic proteins and PPARα, indicating a
decreased susceptibility to apoptosis in colon cancer with
respect to non-neoplastic mucosa. This correlation between
arachidonic acid and susceptibility to apoptosis, to which
these “in vivo” results point, was supported by “in vitro”
experiments, in which exogenously added arachidonic acid
was found to cause apoptosis in colon cancer Caco-2 cells.
Cell death was found to be correlated with the intracellular
level of arachidonic acid. The induction of apoptosis by
arachidonic acid has also been conﬁrmed by other authors
[26].
The decreased percentage of arachidonic acid in tumors
at all Duke’s stages was probably correlated with the
increased expression of COX-2. Previous studies have shown
this enzyme to be increased in colon and rectal cancer [27],
and to not be expressed in non-neoplastic mucosa [27]. The
importance of COX-2 in modulating colon carcinogenesis
has been shown by the observation that NSAIDs prevent
colon cancer and cause apoptosis [28]. The apoptosis-
inducing mechanism might result from the accumulation
of the COX substrate, arachidonic acid, which is a strong
signal for induction of apoptosis: COX-2 may promote
carcinogenesis by lowering the arachidonic acid level and
producing PGE2 [29]. Also “in vitro” results shown here
conﬁrmed that COX-2 inhibitor induces apoptosis.
The mechanism triggered by arachidonic acid which
leads to apoptosis may be ascribed to PPARα modulation.
In fact, the decreased PPARα in tumor specimens compared
to non-neoplastic mucosa was supported by our “in vitro”
study supporting a direct correlation between PPARα and
apoptosis.TheinversecorrelationbetweenPPARαandCOX-
2 shown “in vivo” was conﬁrmed by “in vitro” experiments,
where the highest arachidonic acid concentration, deter-
mining the highest PPARα content, was accompanied by8 Journal of Oncology
a decreaseofCOX-2content.Thisobservationsupportswith
other authors’ studies reporting that PPARα ligands inhibit
COX-2 expression by directly antagonizing NFkB- and AP-
1-mediated signalling pathways [30].
The decrease of PPARα in tumors conﬁrms the obser-
vation of other authors that a signiﬁcant decrease in its
expression is found in human tubular adenomas compared
to normal human colonic epithelial cells [29]. Moreover, the
importance of PPARα in apoptosis has also been seen by
other “in vitro” studies [18, 31], stimulating interest in the
investigation of PPARα as a possible therapeutic target to
prevent colon cancer formation.
5. Conclusions
Thebulkofboth“invivo”and“invitro”resultsstronglysug-
gests that colon cancer cells are characterized by decreased
susceptibility to apoptosis deriving from decreased arachi-
donic acid content, PPARα and proapoptotic proteins, and
increased antiapoptotic proteins and COX-2.
In fact, colon cancer in humans shows a modiﬁed fatty
acid composition in phospholipids, with a reduction in
arachidonic acid content. These changes are associated with
an increase in survival-related parameters. The reduced con-
tent of arachidonic acid is likely related to the carcinogenic
process and protects against the eﬀects of oxidative stress
products, decreasing the susceptibility of cancer cells to
apoptosis. This last observation was supported by treating
Caco-2 cells with arachidonic acid.
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